RetinalGenix exchanges 28M shares for pre-funded warrant; outstanding shares drop to 14.2M

RetinalGenix Technologies Inc.

Exchanged 28,014,540 shares held by Sanovas Ophth for a pre-funded warrant to purchase same number of shares at $0.0001 per share.
Outstanding shares reduced from ~42.2M to 14,166,114 after cancellation of exchanged shares.
Transaction with related party: CEO Jerry Katzman is sole manager of Sanovas Ophth.
Warrant is immediately exercisable and terminates when exercised in full; no new cash received.
Issued under Section 3(a)(9) exemption; no additional consideration was paid.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.